Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “BRCA1/2”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableLooking for participantsNCT07821593
What this trial is testing

Patient Experiences After Risk-Reducing Mastectomy Among Women Carrying BRCA1/2 Pathogenic Variants Without a Diagnosis of Breast Cancer

Who this might be right for
Heredo Familial TumorsPsycho Oncological Support
Fondazione IRCCS Policlinico San Matteo di Pavia 100
Not applicableActive Not RecruitingNCT02653105
What this trial is testing

Women at Risk of Breast Cancer and OLFM4

Who this might be right for
Hereditary Breast and Ovarian Cancer Syndrome
Institut Cancerologie de l'Ouest 150
Not applicableLooking for participantsNCT05378204
What this trial is testing

Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer.

Who this might be right for
Breast Cancer
Institut Claudius Regaud 120
Not applicableStudy completedNCT02087592
What this trial is testing

Feasibility of Lifestyle Intervention in BRCA1/2 Mutation Carriers

Who this might be right for
Hereditary Breast and Ovarian Cancer
Technical University of Munich 69
Testing effectiveness (Phase 2)Active Not RecruitingNCT05498272
What this trial is testing

Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations

Who this might be right for
Prostate CancerBRCA1 MutationBRCA2 Mutation+2 more
Rana McKay, MD 32
Testing effectiveness (Phase 2)Study completedNCT01540565
What this trial is testing

Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
BRCA1 Mutation CarrierBRCA2 Mutation CarrierOvarian Epithelial Tumor+3 more
National Cancer Institute (NCI) 52
Large-scale testing (Phase 3)Active Not RecruitingNCT06783140
What this trial is testing

Study of NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Pancreatic Cancer

Who this might be right for
Pancreatic Cancer, Advanced or MetastaticBRCA1/2 MutationPALB2 Gene Mutation
University Health Network, Toronto 10
Not applicableUnknownNCT01273909
What this trial is testing

Outcomes After Perforator Flap Reconstruction for Breast Reconstruction and/or Lymphedema Treatment

Who this might be right for
Breast CancerHereditary Breast/Ovarian Cancer (brca1, brca2)Acquired Lymphedema+1 more
The National Institute of Lymphology 1,000
Early research (Phase 1)Active Not RecruitingNCT02208375
What this trial is testing

MTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian

Who this might be right for
BRCA1 Mutation CarrierBRCA2 Mutation CarrierEndometrial Adenocarcinoma+13 more
M.D. Anderson Cancer Center 159
Not applicableStudy completedNCT04222465
What this trial is testing

Characterizing the Cross-sectional Approach to Investigate the Prevalence of Tissue BRCA1/2 Mutations in Newly Diagnosed Advanced Ovarian Cancer Patients

Who this might be right for
Ovarian Neoplasms
AstraZeneca 207
Early research (Phase 1)Study completedNCT03685331
What this trial is testing

HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer

Who this might be right for
Metastatic Breast CancerLocally Advanced Breast CancerAdvanced Breast Cancer+2 more
Abramson Cancer Center at Penn Medicine 9
Not applicableLooking for participantsNCT07039552
What this trial is testing

Development and Validation of an Ovarian Cancer Risk Prediction Model for Family Members of Ovarian Cancer Probands

Who this might be right for
Hereditary Breast and Ovarian Cancer SyndromeBRCA Mutations
Peking University Third Hospital 10,000
Early research (Phase 1)Ended earlyNCT05252390
What this trial is testing

NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorOvarian CancerOvary Cancer+24 more
Nuvation Bio Inc. 82
Large-scale testing (Phase 3)Study completedNCT02000622
What this trial is testing

Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.

Who this might be right for
Breast Cancer MetastaticBRCA 1 Gene MutationBRCA 2 Gene Mutation
AstraZeneca 302
Large-scale testing (Phase 3)Looking for participantsNCT06533384
What this trial is testing

PARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC

Who this might be right for
Triple-negative Breast Cancer
Guangdong Provincial People's Hospital 310
Large-scale testing (Phase 3)Looking for participantsNCT06580314
What this trial is testing

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

Who this might be right for
Fallopian Tube Endometrioid AdenocarcinomaFallopian Tube High Grade Serous AdenocarcinomaFallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor+9 more
NRG Oncology 880
Testing effectiveness (Phase 2)Study completedNCT03117933
What this trial is testing

Olaparib +/- Cediranib or Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Who this might be right for
Ovarian Cancer
University of Oxford 139
Not applicableLooking for participantsNCT06775470
What this trial is testing

Impact of Different BRCA1/2 Gene Variants on Response to Therapy and Prognosis of Ovarian Cancer

Who this might be right for
Ovarian Cancer
IRCCS Azienda Ospedaliero-Universitaria di Bologna 300
Large-scale testing (Phase 3)Study completedNCT02282020
What this trial is testing

Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments

Who this might be right for
Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
AstraZeneca 266
Not applicableLooking for participantsNCT01102569
What this trial is testing

Pancreatic Cancer Genetics

Who this might be right for
Pancreatic Cancer
Columbia University 100
Next Page